Navigation Links
LMU Munich researchers highly endowed with EU funding
Date:10/27/2009

Two junior researchers from Ludwig-Maximilians-Universitt (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David Vhringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

Professor Jens Michaelis will be studying how DNA is structurally rearranged in the cell nucleus in his project "ATP-dependent nucleosome remodeling Single molecule studies and super-resolution microscopy". In higher cells, the threadlike DNA molecule wraps around so-called histone proteins, together forming larger units called nucleosomes. Packed tightly like this, the DNA is protected, but sections of it have to be kept constantly accessible. Only so can the genetic information be read and the DNA duplicated for cell division, for example. This restructuring of nucleosomes is therefore an essential cellular process and, despite extensive experimental effort, its mechanistic detail is still not perfectly understood. This is where the 1.4 million euro sponsored project comes in: Michaelis intends to visualize this dynamic and energy-consuming nucleosome restructuring at the molecular level. Highly complex microscopic techniques, some of which originated in the physicist's own lab, will at last help demonstrate this tiny-scale process in a mechanistic model.

Jens Michaelis was born in 1971 in Mainz. After studying physics at Ulm University, he moved to the University of Oregon, USA. Jens Michaelis earned his doctorate in 2000 at Universitt Konstanz with his thesis on "Microscopy with a single-molecule light source". Following this, he worked as a postdoc for three years at the University of Berkeley, USA. In 2003, he came to the Institute of Physical Chemistry of LMU Munich as the head of a research group. For his successful work, he was appointed junior professor in 2006. He has been a professor in the Department of Chemistry and Biochemistry, and has been working in the cluster of excellence Center for Integrated Protein Science Munich (CIPSM) since 2008.

The project "Persistence of allergic sensitization" of Privatdozent David Vhringer shall be funded with the maximum grant of more than 1.7 million Euros. The immunologist intends to study immune factors essential to the onset of allergy. This misguided response by the body's defenses already concerns up to a quarter of the population in the western industrial nations, according to estimates, and the trend is upward. An allergic reaction is triggered by the activation of mast cells and basophilic granulocytes. Both types of immune cell are activated by so-called IgE antibodies, which recognize harmless substances the respective allergens and thus trigger the undesired immune response. The IgE immunoglobulins can bind onto mast cells and basophilic granulocytes and remain in the body for many years, thereby causing the allergy to persist. From a therapeutic perspective, it would be desirable to eliminate IgE-producing B cells selectively. In the scope of his EU-funded project, Vhringer shall be addressing various problems concerning the formation and lifespan of IgE-producing B cells.

David Vhringer was born in 1970 in Stuttgart. He studied biology at the Universities of Tbingen and Freiburg. In Freiburg, he earned his doctorate with his thesis on "T cell mediated autoimmune hepatitis and characterization of the Killer cell Lectin-like Receptor G1". Following that, he worked from 2002 to 2005 as a postdoc at the University of California San Francisco, USA. In 2005, he came to the Institute of Immunology of LMU Munich as the head of an Emmy Noether junior research group. He completed his habilitation in 2008.


'/>"/>

Contact: Dr. Jens Michaelis
michaelis@lmu.de
49-892-180-77561
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related biology news :

1. Environmentally green beer: Munich brewing engineers research energy savings
2. Munich researchers discover new target for tailored antibiotics
3. 2 Alexander von Humboldt professorships go to LMU Munich
4. Munich researchers discover key allergy gene
5. Fighting sleep, Penn researchers reverse the cognitive impairment caused by sleep deprivation
6. UBC researchers find key microbial indicator of ocean health
7. Clemson researchers say algae key to mass extinctionss
8. Texas A&M researchers find new mechanism for circadian rhythm
9. Researchers find ways to encourage spinal cord regeneration after injury
10. CCNY researchers study scientific collaboration in age of internet
11. Carnegie Mellon researchers save electricity with low-power processors and flash memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology: